An updated systematic review evaluates weight-loss ranges across GLP-1 medications, emphasizing safety data and the vital role of sustainable health habits.
On September 1, 2026, an updated systematic review published in the Annals of Internal Medicine presented new findings regarding anti-obesity medications. The comprehensive research evaluated 38 randomized controlled trials. These clinical trials involved 25,816 adults with overweight or obesity who did not have diabetes. This update added 14 new trials to an earlier review. This rapid expansion reflects the growing evidence base for modern metabolic treatments.
Researchers examined a variety of critical health markers alongside overall body-weight changes. These specific markers included body-mass index, waist circumference, and blood pressure. The systematic review evaluated GLP-1 receptor agonists and related co-agonists to provide a clearer picture of expected clinical outcomes.
For years, our team watched smart, capable people blame themselves when standard diet advice failed them. They would cut calories drastically, run themselves into the ground, and inevitably regain the weight. It was heartbreaking to see this cycle repeat constantly. We realized we were treating a complex biological and psychological system like a simple math problem.
The medications evaluated in this updated review address that underlying biological complexity directly. They primarily function by mimicking natural hormones to regulate digestion and metabolic signaling. The review captured a clear shift from a narrow landscape to a broader field of advanced metabolic therapies. This evolving field now includes newer oral agents and complex multi-hormonal drugs.
One such experimental therapy is JNJ-64565111, which acts as a dual GLP-1 and glucagon receptor agonist. These pathways help regulate energy balance more effectively than behavioral changes alone. By targeting multiple hormone receptors simultaneously, newer multiagonists produce significant physiological shifts. The emergence of oral treatments may also expand options for patients preferring non-injectable routes.
The updated review specifically focused on adults with overweight or obesity who did not have a diabetes diagnosis. This specific population parameter is crucial for understanding baseline metabolic responses. Researchers can isolate the weight-loss effects from standard diabetes management protocols. Studying this distinct group helps clinicians understand how these medications function purely for weight and metabolic management.
As the anti-obesity medication evidence base expands, distinguishing between different patient needs becomes essential. Treatment plans must account for an individual's unique metabolic baseline and long-term health goals. A targeted approach ensures that patients receive the most appropriate intervention for their specific biology.
Mainstream media coverage often ranks these medications based solely on their highest reported weight-loss percentages. This creates the illusion that a single drug is definitively superior for everyone. However, the study data tells a much more nuanced story about realistic clinical expectations. Lead author Areesha Moiz of the Lady Davis Institute for Medical Research cautioned against simple numerical rankings.
Moiz noted that efficacy comparisons are not conclusive because treatment periods varied among the therapies. A drug studied over a longer period naturally has a different outcome profile than one studied briefly. Additionally, larger weight reductions do not automatically equal better overall health outcomes. Moiz explained that greater weight loss with newer multiagonists did not necessarily produce proportionally greater improvements in blood pressure.
This finding highlights why evaluating metabolic health requires looking far beyond the bathroom scale. Most importantly, none of these medications were evaluated in isolation during the trials. Every included trial incorporated lifestyle intervention, physical activity, and targeted nutrition counseling. The dietary guidance specifically emphasized protein, fiber, and micronutrient intake.
Because trials paired medication with behavioral support, patients cannot expect identical results from medication alone. Successful weight management requires dietary interventions that support systemic health alongside medical treatments. Nutrition plays a vital role in preserving physical function during periods of reduced caloric intake.
Patients must prioritize adequate nutrition to support tracking body composition and protecting muscle while losing weight. Clinical trials rely on these foundational habits to maximize the safety and efficacy of the treatments. Medication should be viewed as a powerful tool that amplifies the benefits of sustainable daily routines.
The systematic review provided a detailed breakdown of approximate placebo-subtracted weight loss across different medications. This specific metric represents the difference between active treatment and placebo results. It is important to remember that these figures are population averages rather than guaranteed individual outcomes. Among commercially available therapies, tirzepatide produced the largest placebo-subtracted weight reduction at approximately 19 percent.
A separate summary reported a precise estimate of 19.0 percent for tirzepatide. For other established options, semaglutide reached approximately 15 percent, while liraglutide produced roughly 6 percent. More precise estimates placed injectable semaglutide at 14.8 percent and liraglutide at 5.8 percent. The review also examined newer oral treatments like orforglipron, which yielded approximately 12.4 percent placebo-subtracted weight loss.
Some semaglutide studies in this updated review notably utilized a higher 7.2-mg dose rather than the previously studied 2.4-mg dose. The review also highlighted emerging multiagonists that are still under clinical development. Retatrutide produced a placebo-subtracted weight loss of approximately 22.1 percent. Meanwhile, amycretin yielded an estimated 23.9 percent reduction.
This updated review included the first long-term head-to-head trials comparing these medications directly. These specific comparisons offer valuable insight into why individual responses to these treatments differ across patient populations. Researchers found greater weight reduction with tirzepatide compared to semaglutide. Similarly, semaglutide produced greater weight loss than liraglutide in direct clinical comparisons.
A combination therapy of cagrilintide-semaglutide also outperformed semaglutide alone. Experimental therapies demonstrated notable results in these direct evaluations as well. The experimental dual agonist JNJ-64565111 reported greater weight loss than liraglutide in a head-to-head trial. These detailed comparisons help providers select the most effective starting point for new patients.
Understanding side effects is a crucial part of the shared decision-making process between patients and clinicians. Gastrointestinal adverse events were common across the clinical trials. One summary noted these events occurred in approximately 76.0 percent of active-treatment participants compared with 40.1 percent of placebo participants. While gastrointestinal effects remained the most common adverse events, the authors identified no new safety signals.
Discontinuation because of adverse events was reported at 10.7 percent with active treatment versus 3.4 percent with placebo. Serious adverse events occurred in 6.5 percent of the active-treatment groups and 5.2 percent of the placebo groups. Deaths were extremely rare, reported at 0.1 percent for active treatment and 0.0 percent for placebo. The medications differ significantly in tolerability, administration route, dosing frequency, and long-term evidence.
Trust in clinical data requires transparency regarding how studies are funded and conducted. The lead author of this systematic review was Areesha Moiz of the Jewish General Hospital in Montreal. The comprehensive study was conducted entirely without external funding. This structural independence allows the medical community to evaluate the data objectively.
Furthermore, both Moiz and expert commentator George Fantus reported no relevant financial relationships. This independence strengthens the credibility of the clinical findings significantly. It allows patients and healthcare providers to evaluate the data without concerns about pharmaceutical industry influence. Objective data remains the most reliable foundation for making critical health decisions.
While the clinical trial data is robust, critical questions remain about long-term real-world application. George Fantus, MD, a McGill University professor who provided expert commentary, emphasized this exact point. Fantus stated that longer follow-up is necessary to assess outcomes beyond blood pressure and determine which benefits accrue over time. We need comprehensive data tracking how these treatments affect holistic health markers over several years.
Conditions linked to obesity require extended observation to monitor metabolic liver disease, abnormal lipid levels, and sleep apnea. The medications differ substantially in administration route, dosing frequency, and overall treatment burden. These practical differences mean the drugs should never be treated as interchangeable by patients or providers. Future research must evaluate how these real-world factors impact long-term patient adherence.
Practical barriers also require significant attention from researchers and healthcare policymakers. Fantus argued that limited coverage and constrained healthcare budgets remain important obstacles to access. A medication's clinical efficacy means very little if patients cannot reliably obtain or afford it. Combining evidence-based medical treatment with sustainable habits remains the most reliable path toward lasting metabolic health.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
